This Biotech ETF Looks Primed To Rally Again

biotech-white-pills
The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016 posting a loss of more than 20%, has started posting gains again and is looking like the rally may be poised to continue.
NASDAQ:IBB February 20, 2017 6:42am

A Major Recovery Is Brewing In The Biotech & Healthcare Space

white-pills
From Taki Tsaklanos: Biotechnology was once the darling of stock market investors. Not so anymore, since the summer of 2015 the sector collapsed from 400 points to 250 points in the IBB ETF.
NASDAQ:IBB February 17, 2017 6:33am

Biotech’s Next Big Catalyst Could Be Synthetic DNA

biotech-dna
From Jon Markman: It really is a brave new world. Not long ago, a group of prominent scientists announced plans for a project to create synthetic human DNA from scratch.
NASDAQ:IBB February 14, 2017 9:21am

Biotech ETF Recovery Powered By Big Earnings Improvements

biotech-medical-pills
From Zacks: The biotech industry, which was shunned by investors last year, made a strong comeback following Trump’s victory in anticipation of softer regulation.
NASDAQ:IBB February 10, 2017 10:49am

Biotech ETF Surges On Positive Trump Comments

donald trump
The iShares Nasdaq Biotechnology Index Fund (IBB) outperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a dollar basis, producing a +2.84% one-day return and outperforming the wider markets by a total of 2.85 percentage points.
NASDAQ:IBB January 31, 2017 5:51pm

Can Biotech ETFs Survive A Trump Presidency?

biotech-medical-pills
From Zacks: Biotech stocks have been under intense pressure for more than a year now with sector-specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario weighing on the sector.
NASDAQ:IBB January 28, 2017 9:37am

Biotech Lags Again, IBB Closes Down Nearly 1% To Trail All ETFs

biotech-dna
The iShares Nasdaq Biotechnology Index Fund (IBB) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -0.94% one-day return and trailing the wider markets by a total of 0.68 percentage points.
NASDAQ:IBB January 24, 2017 7:19am

So Much For The Bounce: IBB, Down 0.85%, Is Today’s Biggest ETF Loser

biotech-medical-pills
The iShares Nasdaq Biotechnology Index Fund (IBB) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -0.84% one-day return and trailing the wider markets by a total of 0.47 percentage points.
NASDAQ:IBB January 19, 2017 6:53pm

IBB Bounces Back, Is Today’s Best Performing ETF On A Dollar Basis

biotech-white-pills
The iShares Nasdaq Biotechnology Index Fund (IBB) outperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a dollar basis, producing a +0.83% one-day return and outperforming the wider markets by a total of 0.61 percentage points.
NASDAQ:IBB January 18, 2017 5:08pm

The IBB Trailed All Major ETFs Today, With A Nearly 2% Drop

Arrow down
The iShares Nasdaq Biotechnology Index Fund (IBB) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -1.96% one-day return and trailing the wider markets by a total of 1.61 percentage points.
NASDAQ:IBB January 17, 2017 5:16pm

Can Biotechs Recover From Trump’s Strong Condemnation?

biotech
From Zacks: The pharma and biotech industry is a victim of concerns over increased regulatory scrutiny on high drug prices over the past two years. The worries cooled down after Trump’s victory, and gave biotech stocks a shot in the arm.
NASDAQ:IBB January 13, 2017 9:13am

Biotech ETFs Could Be Poised For A New Rally

biotech-medical-pills
From Taki Tsaklanos: Recently, we spotted the potential of a breakdown in biotechnology stocks, see Biotechnology Stocks Have News For Investors: It is Now or Never. We warned readers to be on the safe side, as a breakdown scenario would be significant.
NASDAQ:IBB January 9, 2017 8:22am

Biotech Downturn Underscored By Lack Of New Drug Approvals

biotech-medical-pills
Following the astronomical gains of the previous several years, the biotech industry was hammered in 2016. Behind the decline was a huge downturn in the approval of new medicines.
NASDAQ:IBB January 2, 2017 10:31am

These Biotech Plays More Than Doubled This Year

biotech-white-pills
From Zacks: 2016 has not been a great year for biotech stocks which were under intense pressure with issues like increasing political and media focus on high price tags for drugs and the changing competitive scenario weighing on the sector.
NASDAQ:IBB December 22, 2016 11:18am

Recommended for You

Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories